Immuno Oncology Assay Market Outlook from 2024 to 2034

The immuno-oncology assay market is estimated to be valued at US$ 5.6 billion in 2024. The immuno-oncology assay market is predicted to rise at a CAGR of 12.4% from 2024 to 2034. The global immuno-oncology assay market is anticipated to reach US$ 18.1 billion by 2034.

The immuno-oncology assay market is experiencing rapid growth, driven by the increasing prevalence of cancer globally and advancements in cancer immunotherapy. Immuno-oncology assays are critical tools for diagnosing cancer, predicting patient responses to treatment, and monitoring therapeutic efficacy by assessing the immune system's interactions with cancer cells.

Technological advancements play a significant role in the market's growth, with next-generation sequencing (NGS), flow cytometry, PCR, and immunoassays continuously improving assay sensitivity, specificity, and multiplexing capabilities. These innovations enable the identification of novel biomarkers and the development of companion diagnostics for personalized cancer treatment strategies.

Attributes Key Insights
Estimated Market Size in 2024 US$ 5.6 billion
Projected Market Value in 2034 US$ 18.1 billion
Value-based CAGR from 2024 to 2034 12.4%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2019 to 2023 Historical Analysis vs. 2024 to 2034 Market Forecast Projections

From 2019 to 2023, the immuno-oncology assay market experienced a CAGR of 15.4%. The approval of immune checkpoint inhibitors revolutionized cancer treatment, leading to a surge in immuno-oncology research and development.

The immuno-oncology assay market witnessed rapid growth, fueled by increasing investments in research and clinical trials. Technological advancements, such as next-generation sequencing and multiplexed immunoassays, improved assay sensitivity and specificity. Regulatory approvals for companion diagnostics further accelerated market expansion.

The immuno-oncology assay market is expected to evolve further, with a focus on predictive and prognostic biomarkers, early cancer detection, and monitoring of treatment responses. Strategic collaborations, regulatory support, and reimbursement policies will continue to shape market dynamics.

The immuno-oncology assay market is poised for significant growth in the coming years, driven by ongoing advancements in cancer research, therapeutic innovation, and the increasing adoption of personalized medicine approaches in oncology.

Projections indicate that the global immuno-oncology assay market is expected to experience a CAGR of 12.4% from 2024 to 2034.

Historical CAGR from 2019 to 2023 15.4%
Forecast CAGR from 2024 to 2034 12.4%

Immuno Oncology Assay Market Growth Drivers

  • The increasing prevalence of cancer worldwide, attributed to factors such as aging populations, lifestyle changes, and environmental factors, is a significant driver for immuno-oncology assay market growth.
  • Favorable regulatory frameworks and government initiatives aimed at accelerating the development and commercialization of innovative oncology diagnostics contribute to market growth.
  • Pharmaceutical companies, biotechnology firms, and academic institutions are heavily investing in research and development activities focused on immuno-oncology assays.
  • Immuno-oncology assays play a critical role in identifying predictive and prognostic biomarkers, guiding treatment decisions, and stratifying patient populations for targeted therapies, thereby driving market growth.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Immuno Oncology Assay Market Key Challenges

  • Developing assays that accurately reflect these interactions, including immune cell activation, suppression, and evasion mechanisms, poses a significant challenge.
  • High costs may limit patient access to these assays, particularly in resource-limited settings or regions with constrained healthcare budgets. Ensuring affordability and accessibility while maintaining assay quality and performance is a significant challenge.
  • Oncologists and pathologists may require training to interpret assay results effectively and incorporate them into treatment decision-making. Integrating immuno-oncology assays into existing clinical workflows without disrupting patient care can be challenging.

Country-wise Analysis

South Korea and Japan stand out as the top two revenue-generating countries, as indicated in the table provided. The government and private sector investments in cancer research and immunotherapy initiatives are significant drivers of market growth in South Korea.

Japanese pharmaceutical companies are at the forefront of developing immunotherapy drugs and companion diagnostics. Regulatory support and streamlined approval processes for diagnostic products contribute to market growth.

Countries Forecast CAGRs from 2024 to 2034
The United States 12.1%
The United Kingdom 13.9%
China 13.3%
Japan 14.1%
South Korea 15.2%

Advancements in Cancer Diagnostics and Therapeutics Propel Growth of Immuno-Oncology Assay Market in the United States

The immune-oncology assay market in the United States is expected to expand at a CAGR of 12.1% by 2034. The United States is at the forefront of cancer immunotherapy research and development, with significant investments from both public and private sectors.

The approval and adoption of novel immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies, have propelled the demand for immuno-oncology assays to assess treatment efficacy and patient response.

The United States-based companies and research institutions are driving innovations in immuno-oncology assay technologies, including next-generation sequencing, flow cytometry, and multiplexed immunoassays. These technological advancements enhance assay sensitivity, specificity, and throughput, enabling comprehensive profiling of the tumor microenvironment and immune response.

The Growing Innovation in Technology to Boost Market Growth in the United Kingdom

The immune-oncology assay market in the United Kingdom is expected to expand at a CAGR of 13.9% by 2034. The United Kingdom is home to leading research institutions, universities, and biotechnology companies actively engaged in immuno-oncology research and development.

Collaborative efforts between academia, industry, and government agencies fuel innovation in assay technologies, biomarker discovery, and therapeutic development, driving market growth.

The United Kingdom is a significant hub for clinical trials evaluating immunotherapies across various cancer types. The adoption of immune checkpoint inhibitors, CAR-T cell therapies, and other immunotherapeutic agents in clinical practice is increasing, necessitating the use of immuno-oncology assays for patient selection, treatment monitoring, and outcome prediction.

Government Support Drives Significant Growth of Immuno-Oncology Assay Market in China

China faces a significant burden of cancer, with increasing incidence rates due to factors such as aging population, lifestyle changes, and environmental pollution.

This high disease burden drives the demand for immuno-oncology assays for early detection, diagnosis, and treatment monitoring. United Kingdom. The immune-oncology assay market in China is expected to rise at a CAGR of 13.3% by 2034.

The Chinese government has prioritized cancer prevention, diagnosis, and treatment as part of its healthcare reforms. Initiatives to improve cancer care infrastructure, enhance access to innovative therapies, and promote research and development in oncology contribute to market growth.

Advancements in Cancer Research Propel Growth of Immuno-Oncology Assay Market in Japan

Japan has a growing cancer burden due to factors such as the aging population, lifestyle changes, and environmental factors. The rising prevalence of cancer drives the demand for immuno-oncology assays for early detection, diagnosis, and treatment monitoring. The immune-oncology assay market in Japan is expected to expand at a CAGR of 14.1% by 2034.

Japan has a strong research and development infrastructure in oncology, with leading academic institutions, biotechnology companies, and healthcare centers engaged in cancer research.

The country's contributions to cancer immunotherapy research, including novel therapies and biomarker discovery, fuel the demand for immuno-oncology assays.

Advancements in Cancer Immunotherapy Fuel the Growth of Immuno-Oncology Assay Market in South Korea

South Korea is actively involved in cancer immunotherapy research and development. The adoption of immune checkpoint inhibitors, CAR-T cell therapies, and other immunotherapeutic agents is increasing, driving the demand for immuno-oncology assays to assess treatment efficacy and patient response. The immune-oncology assay market in South Korea is expected to flourish at a CAGR of 15.2% by 2034.

South Korean companies are at the forefront of technological innovation in diagnostics and biotechnology. They are developing advanced immuno-oncology assay platforms, including next-generation sequencing, flow cytometry, and multiplexed immunoassays, to meet the evolving needs of cancer diagnosis and treatment.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

The below section shows the leading segment. The reagents and antibodies segment is to rise at a CAGR of 12.2% from 2024 to 2034. Based on technology, the checkpoint inhibitors segment is anticipated to hold a dominant share through 2034. It is set to exhibit a CAGR of 11.9% from 2024 to 2034.

Category CAGR from 2024 to 2034
Reagents and Antibodies 12.2%
Checkpoint Inhibitors 11.9%

Reagents and Antibodies Segment to Remain Prominent Throughout the Forecast Period

Based on type, the Reagents and Antibodies segment is anticipated to proliferate at a CAGR of 12.2% from 2024 to 2034.

Reagents and antibodies are essential components of immuno-oncology assays, playing crucial roles in detecting specific biomarkers, antigens, or immune cell markers associated with cancer and immunotherapy response.

Reagents and antibodies are highly specific and sensitive, allowing for the accurate detection and quantification of targets of interest in complex biological samples, such as blood, tissue, or tumor specimens.

Many immuno-oncology assays require multiplexing, where multiple targets are detected simultaneously in a single assay. Reagents and antibodies with multiplexing capabilities enable comprehensive profiling of the immune response and tumor microenvironment, providing valuable insights for cancer diagnosis and treatment.

The Demand for Checkpoint Inhibitors Segment Remains High

Based on technology, the checkpoint inhibitors segment is anticipated to rise at a CAGR of 11.9% from 2024 to 2034.

Checkpoint inhibitors have revolutionized cancer treatment by enhancing the body's immune response against cancer cells. These therapies block inhibitory checkpoints, such as PD-1/PD-L1 and CTLA-4, allowing the immune system to recognize and attack cancer cells more effectively.

Biomarkers such as PD-L1 expression levels have been identified as predictors of response to checkpoint inhibitor therapy. Immuno-oncology assays are used to measure these biomarkers, allowing clinicians to identify patients who are most likely to respond to checkpoint inhibitors and tailor treatment accordingly.

The growing number of clinical trials investigating checkpoint inhibitors and combination therapies underscores their importance in immuno-oncology research. Immuno-oncology assays play a crucial role in these trials by assessing biomarker expression, immune cell profiling, and treatment responses.

Competitive Landscape

Collaboration with academic institutions, research organizations, and biotechnology companies enables market players to access complementary expertise, technologies, and resources.

Partnerships facilitate biomarker discovery and validation, clinical validation studies, and the development of companion diagnostics. Collaborations also enhance market penetration, accelerate product development, and mitigate development risks.

  • Agilent Technologies: Agilent offers a range of solutions for immuno-oncology research, including genomic profiling technologies, such as microarrays and next-generation sequencing (NGS), as well as protein analysis tools like mass spectrometry and immunoassays.
  • Sartorius AG: Sartorius provides innovative laboratory instruments and consumables for cell analysis, cell culture, and protein analysis, which are essential for immuno-oncology assay development and research.
  • NanoString Technologies: NanoString specializes in molecular profiling technologies, particularly its nCounter platform, which enables highly multiplexed gene expression analysis. This platform is valuable for biomarker discovery and immune profiling in immuno-oncology research.

Key Coverage in Immuno-Oncology Assay Market Report

  • Immuno-Oncology Assay Market Size, Current Insights and Demographic Trends
  • Immuno-Oncology Assay Market Revenue & Trends
  • Reasons for Expanding Immuno-Oncology Assay Market
  • Factors Propelling the Global Immuno-Oncology Assay Market
  • Promising Opportunities for Immuno-Oncology Assay in the Middle East and Africa Market

Report Scope

Attributes Details
Estimated Market Size in 2024 US$ 5.6 billion
Projected Market Valuation in 2034 US$ 18.1 billion
Value-based CAGR 2024 to 2034 12.4 %
Forecast Period 2024 to 2034
Historical Data Available for 2019 to 2023
Market Analysis Value in US$ billion
Key Regions Covered
  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • Middle East and Africa
Key Market Segments Covered
  • Product
  • Technology
  • Indication
  • End-user
  • Application
  • Region
Key Countries Profiled
  • The United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • Russia
  • Poland
  • Czech Republic
  • Romania
  • India
  • Bangladesh
  • Australia
  • New Zealand
  • China
  • Japan
  • South Korea
  • GCC countries
  • South Africa
  • Israel
Key Companies Profiled
  • AGILENT TECHNOLOGIES
  • Sartorius AG
  • NanoString Technologies
  • THERMO FISHER SCIENTIFIC
  • BIO-RAD LABORATORIES
  • F. HOFFMANN-LA ROCHE LTD.
  • PERKINELMER
  • ILLUMINA
  • QIAGEN N.V.
  • Charles River Laboratories

Immuno Oncology Assay Market - Key Segments

By Product:

  • Reagents and Antibodies
  • Instruments
  • Software
  • Consumables and Accessories

By Technology:

  • Checkpoint Inhibitors
  • Cytokines & Immunomodulators
  • Monoclonal Antibodies
  • Other Technologies

By indication:

  • Melanoma
  • Colorectal Cancer
  • Lung Cancer
  • Other Cancers

By End-User:

  • Hospitals
  • Clinics
  • Cancer Research Centers

By Application:

  • Research Applications
  • Clinical Diagnostics

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • Middle East and Africa

Frequently Asked Questions

What is the expected worth of the immuno-oncology assay market in 2024?

As of 2024, the market for immune oncology assays is expected to be valued at US$ 5.6 billion.

What is the anticipated market value for the immuno-oncology assay in 2034?

By 2034, the market value of immuno-oncology assays is expected to reach US$ 18.1 billion.

What is the projected forecast CAGR for the immuno-oncology assay market from 2024 to 2034?

From 2024 to 2034, the immuno-oncology assay market is expected to flourish at a CAGR of 12.4%

Based on product, which segment dominates the immuno-oncology assay market?

The reagent and antibodies segment is expected to rise at a CAGR of 12.2% from 2024 to 2034.

Which country is likely to be at the pinnacle of the market?

South Kore is likely the top-performing market, with a CAGR of 15.2%.

Table of Content
1. Executive Summary
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Investment Feasibility Matrix
    3.5. PESTLE and Porter’s Analysis
    3.6. Regulatory Landscape
        3.6.1. By Key Regions
        3.6.2. By Key Countries
    3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
    4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
    4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2019 to 2023
    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2024 to 2034
        5.3.1. Reagents and Antibodies
        5.3.2. Instruments
        5.3.3. Software
        5.3.4. Consumables and Accessories
    5.4. Y-o-Y Growth Trend Analysis By Product, 2019 to 2023
    5.5. Absolute $ Opportunity Analysis By Product, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Technology
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2019 to 2023
    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2024 to 2034
        6.3.1. Checkpoint Inhibitors
        6.3.2. Cytokines & Immunomodulators
        6.3.3. Monoclonal Antibodies
        6.3.4. Other Technologies
    6.4. Y-o-Y Growth Trend Analysis By Technology, 2019 to 2023
    6.5. Absolute $ Opportunity Analysis By Technology, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication 
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2019 to 2023
    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2024 to 2034
        7.3.1. Melanoma
        7.3.2. Colorectal Cancer
        7.3.3. Lung Cancer
        7.3.4. Other Cancers
    7.4. Y-o-Y Growth Trend Analysis By Indication, 2019 to 2023
    7.5. Absolute $ Opportunity Analysis By Indication, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-Users
    8.1. Introduction / Key Findings
    8.2. Historical Market Size Value (US$ Million) Analysis By End-Users, 2019 to 2023
    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-Users, 2024 to 2034
        8.3.1. Hospitals
        8.3.2. Clinics
        8.3.3. Cancer Research Centers
    8.4. Y-o-Y Growth Trend Analysis By End-Users, 2019 to 2023
    8.5. Absolute $ Opportunity Analysis By End-Users, 2024 to 2034
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
    9.1. Introduction / Key Findings
    9.2. Historical Market Size Value (US$ Million) Analysis By Application, 2019 to 2023
    9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2024 to 2034
        9.3.1. Research Applications
        9.3.2. Clinical Diagnostics
    9.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023
    9.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
    10.1. Introduction
    10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
    10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
        10.3.1. North America
        10.3.2. Latin America
        10.3.3. Western Europe
        10.3.4. Eastern Europe
        10.3.5. South Asia and Pacific
        10.3.6. East Asia
        10.3.7. Middle East and Africa
    10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        11.2.1. By Country
            11.2.1.1. USA
            11.2.1.2. Canada
        11.2.2. By Product
        11.2.3. By Technology
        11.2.4. By Indication
        11.2.5. By End-Users
        11.2.6. By Application
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Product
        11.3.3. By Technology
        11.3.4. By Indication
        11.3.5. By End-Users
        11.3.6. By Application
    11.4. Key Takeaways
12. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        12.2.1. By Country
            12.2.1.1. Brazil
            12.2.1.2. Mexico
            12.2.1.3. Rest of Latin America
        12.2.2. By Product
        12.2.3. By Technology
        12.2.4. By Indication
        12.2.5. By End-Users
        12.2.6. By Application
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Product
        12.3.3. By Technology
        12.3.4. By Indication
        12.3.5. By End-Users
        12.3.6. By Application
    12.4. Key Takeaways
13. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        13.2.1. By Country
            13.2.1.1. Germany
            13.2.1.2. UK
            13.2.1.3. France
            13.2.1.4. Spain
            13.2.1.5. Italy
            13.2.1.6. Rest of Western Europe
        13.2.2. By Product
        13.2.3. By Technology
        13.2.4. By Indication
        13.2.5. By End-Users
        13.2.6. By Application
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Product
        13.3.3. By Technology
        13.3.4. By Indication
        13.3.5. By End-Users
        13.3.6. By Application
    13.4. Key Takeaways
14. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        14.2.1. By Country
            14.2.1.1. Poland
            14.2.1.2. Russia
            14.2.1.3. Czech Republic
            14.2.1.4. Romania
            14.2.1.5. Rest of Eastern Europe
        14.2.2. By Product
        14.2.3. By Technology
        14.2.4. By Indication
        14.2.5. By End-Users
        14.2.6. By Application
    14.3. Market Attractiveness Analysis
        14.3.1. By Country
        14.3.2. By Product
        14.3.3. By Technology
        14.3.4. By Indication
        14.3.5. By End-Users
        14.3.6. By Application
    14.4. Key Takeaways
15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        15.2.1. By Country
            15.2.1.1. India
            15.2.1.2. Bangladesh
            15.2.1.3. Australia
            15.2.1.4. New Zealand
            15.2.1.5. Rest of South Asia and Pacific
        15.2.2. By Product
        15.2.3. By Technology
        15.2.4. By Indication
        15.2.5. By End-Users
        15.2.6. By Application
    15.3. Market Attractiveness Analysis
        15.3.1. By Country
        15.3.2. By Product
        15.3.3. By Technology
        15.3.4. By Indication
        15.3.5. By End-Users
        15.3.6. By Application
    15.4. Key Takeaways
16. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        16.2.1. By Country
            16.2.1.1. China
            16.2.1.2. Japan
            16.2.1.3. South Korea
        16.2.2. By Product
        16.2.3. By Technology
        16.2.4. By Indication
        16.2.5. By End-Users
        16.2.6. By Application
    16.3. Market Attractiveness Analysis
        16.3.1. By Country
        16.3.2. By Product
        16.3.3. By Technology
        16.3.4. By Indication
        16.3.5. By End-Users
        16.3.6. By Application
    16.4. Key Takeaways
17. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
    17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
        17.2.1. By Country
            17.2.1.1. GCC Countries
            17.2.1.2. South Africa
            17.2.1.3. Israel
            17.2.1.4. Rest of MEA
        17.2.2. By Product
        17.2.3. By Technology
        17.2.4. By Indication
        17.2.5. By End-Users
        17.2.6. By Application
    17.3. Market Attractiveness Analysis
        17.3.1. By Country
        17.3.2. By Product
        17.3.3. By Technology
        17.3.4. By Indication
        17.3.5. By End-Users
        17.3.6. By Application
    17.4. Key Takeaways
18. Key Countries Market Analysis
    18.1. USA
        18.1.1. Pricing Analysis
        18.1.2. Market Share Analysis, 2023
            18.1.2.1. By Product
            18.1.2.2. By Technology
            18.1.2.3. By Indication
            18.1.2.4. By End-Users
            18.1.2.5. By Application
    18.2. Canada
        18.2.1. Pricing Analysis
        18.2.2. Market Share Analysis, 2023
            18.2.2.1. By Product
            18.2.2.2. By Technology
            18.2.2.3. By Indication
            18.2.2.4. By End-Users
            18.2.2.5. By Application
    18.3. Brazil
        18.3.1. Pricing Analysis
        18.3.2. Market Share Analysis, 2023
            18.3.2.1. By Product
            18.3.2.2. By Technology
            18.3.2.3. By Indication
            18.3.2.4. By End-Users
            18.3.2.5. By Application
    18.4. Mexico
        18.4.1. Pricing Analysis
        18.4.2. Market Share Analysis, 2023
            18.4.2.1. By Product
            18.4.2.2. By Technology
            18.4.2.3. By Indication
            18.4.2.4. By End-Users
            18.4.2.5. By Application
    18.5. Germany
        18.5.1. Pricing Analysis
        18.5.2. Market Share Analysis, 2023
            18.5.2.1. By Product
            18.5.2.2. By Technology
            18.5.2.3. By Indication
            18.5.2.4. By End-Users
            18.5.2.5. By Application
    18.6. UK
        18.6.1. Pricing Analysis
        18.6.2. Market Share Analysis, 2023
            18.6.2.1. By Product
            18.6.2.2. By Technology
            18.6.2.3. By Indication
            18.6.2.4. By End-Users
            18.6.2.5. By Application
    18.7. France
        18.7.1. Pricing Analysis
        18.7.2. Market Share Analysis, 2023
            18.7.2.1. By Product
            18.7.2.2. By Technology
            18.7.2.3. By Indication
            18.7.2.4. By End-Users
            18.7.2.5. By Application
    18.8. Spain
        18.8.1. Pricing Analysis
        18.8.2. Market Share Analysis, 2023
            18.8.2.1. By Product
            18.8.2.2. By Technology
            18.8.2.3. By Indication
            18.8.2.4. By End-Users
            18.8.2.5. By Application
    18.9. Italy
        18.9.1. Pricing Analysis
        18.9.2. Market Share Analysis, 2023
            18.9.2.1. By Product
            18.9.2.2. By Technology
            18.9.2.3. By Indication
            18.9.2.4. By End-Users
            18.9.2.5. By Application
    18.10. Poland
        18.10.1. Pricing Analysis
        18.10.2. Market Share Analysis, 2023
            18.10.2.1. By Product
            18.10.2.2. By Technology
            18.10.2.3. By Indication
            18.10.2.4. By End-Users
            18.10.2.5. By Application
    18.11. Russia
        18.11.1. Pricing Analysis
        18.11.2. Market Share Analysis, 2023
            18.11.2.1. By Product
            18.11.2.2. By Technology
            18.11.2.3. By Indication
            18.11.2.4. By End-Users
            18.11.2.5. By Application
    18.12. Czech Republic
        18.12.1. Pricing Analysis
        18.12.2. Market Share Analysis, 2023
            18.12.2.1. By Product
            18.12.2.2. By Technology
            18.12.2.3. By Indication
            18.12.2.4. By End-Users
            18.12.2.5. By Application
    18.13. Romania
        18.13.1. Pricing Analysis
        18.13.2. Market Share Analysis, 2023
            18.13.2.1. By Product
            18.13.2.2. By Technology
            18.13.2.3. By Indication
            18.13.2.4. By End-Users
            18.13.2.5. By Application
    18.14. India
        18.14.1. Pricing Analysis
        18.14.2. Market Share Analysis, 2023
            18.14.2.1. By Product
            18.14.2.2. By Technology
            18.14.2.3. By Indication
            18.14.2.4. By End-Users
            18.14.2.5. By Application
    18.15. Bangladesh
        18.15.1. Pricing Analysis
        18.15.2. Market Share Analysis, 2023
            18.15.2.1. By Product
            18.15.2.2. By Technology
            18.15.2.3. By Indication
            18.15.2.4. By End-Users
            18.15.2.5. By Application
    18.16. Australia
        18.16.1. Pricing Analysis
        18.16.2. Market Share Analysis, 2023
            18.16.2.1. By Product
            18.16.2.2. By Technology
            18.16.2.3. By Indication
            18.16.2.4. By End-Users
            18.16.2.5. By Application
    18.17. New Zealand
        18.17.1. Pricing Analysis
        18.17.2. Market Share Analysis, 2023
            18.17.2.1. By Product
            18.17.2.2. By Technology
            18.17.2.3. By Indication
            18.17.2.4. By End-Users
            18.17.2.5. By Application
    18.18. China
        18.18.1. Pricing Analysis
        18.18.2. Market Share Analysis, 2023
            18.18.2.1. By Product
            18.18.2.2. By Technology
            18.18.2.3. By Indication
            18.18.2.4. By End-Users
            18.18.2.5. By Application
    18.19. Japan
        18.19.1. Pricing Analysis
        18.19.2. Market Share Analysis, 2023
            18.19.2.1. By Product
            18.19.2.2. By Technology
            18.19.2.3. By Indication
            18.19.2.4. By End-Users
            18.19.2.5. By Application
    18.20. South Korea
        18.20.1. Pricing Analysis
        18.20.2. Market Share Analysis, 2023
            18.20.2.1. By Product
            18.20.2.2. By Technology
            18.20.2.3. By Indication
            18.20.2.4. By End-Users
            18.20.2.5. By Application
    18.21. GCC Countries
        18.21.1. Pricing Analysis
        18.21.2. Market Share Analysis, 2023
            18.21.2.1. By Product
            18.21.2.2. By Technology
            18.21.2.3. By Indication
            18.21.2.4. By End-Users
            18.21.2.5. By Application
    18.22. South Africa
        18.22.1. Pricing Analysis
        18.22.2. Market Share Analysis, 2023
            18.22.2.1. By Product
            18.22.2.2. By Technology
            18.22.2.3. By Indication
            18.22.2.4. By End-Users
            18.22.2.5. By Application
    18.23. Israel
        18.23.1. Pricing Analysis
        18.23.2. Market Share Analysis, 2023
            18.23.2.1. By Product
            18.23.2.2. By Technology
            18.23.2.3. By Indication
            18.23.2.4. By End-Users
            18.23.2.5. By Application
19. Market Structure Analysis
    19.1. Competition Dashboard
    19.2. Competition Benchmarking
    19.3. Market Share Analysis of Top Players
        19.3.1. By Regional
        19.3.2. By Product
        19.3.3. By Technology
        19.3.4. By Indication
        19.3.5. By End-Users
        19.3.6. By Application
20. Competition Analysis
    20.1. Competition Deep Dive
        20.1.1. AGILENT TECHNOLOGIES
            20.1.1.1. Overview
            20.1.1.2. Product Portfolio
            20.1.1.3. Profitability by Market Segments
            20.1.1.4. Sales Footprint
            20.1.1.5. Strategy Overview
                20.1.1.5.1. Marketing Strategy
        20.1.2. Sartorius AG
            20.1.2.1. Overview
            20.1.2.2. Product Portfolio
            20.1.2.3. Profitability by Market Segments
            20.1.2.4. Sales Footprint
            20.1.2.5. Strategy Overview
                20.1.2.5.1. Marketing Strategy
        20.1.3. NanoString Technologies
            20.1.3.1. Overview
            20.1.3.2. Product Portfolio
            20.1.3.3. Profitability by Market Segments
            20.1.3.4. Sales Footprint
            20.1.3.5. Strategy Overview
                20.1.3.5.1. Marketing Strategy
        20.1.4. THERMO FISHER SCIENTIFIC
            20.1.4.1. Overview
            20.1.4.2. Product Portfolio
            20.1.4.3. Profitability by Market Segments
            20.1.4.4. Sales Footprint
            20.1.4.5. Strategy Overview
                20.1.4.5.1. Marketing Strategy
        20.1.5. BIO-RAD LABORATORIES
            20.1.5.1. Overview
            20.1.5.2. Product Portfolio
            20.1.5.3. Profitability by Market Segments
            20.1.5.4. Sales Footprint
            20.1.5.5. Strategy Overview
                20.1.5.5.1. Marketing Strategy
        20.1.6. F. HOFFMANN-LA ROCHE LTD.
            20.1.6.1. Overview
            20.1.6.2. Product Portfolio
            20.1.6.3. Profitability by Market Segments
            20.1.6.4. Sales Footprint
            20.1.6.5. Strategy Overview
                20.1.6.5.1. Marketing Strategy
        20.1.7. PERKINELMER
            20.1.7.1. Overview
            20.1.7.2. Product Portfolio
            20.1.7.3. Profitability by Market Segments
            20.1.7.4. Sales Footprint
            20.1.7.5. Strategy Overview
                20.1.7.5.1. Marketing Strategy
        20.1.8. ILLUMINA
            20.1.8.1. Overview
            20.1.8.2. Product Portfolio
            20.1.8.3. Profitability by Market Segments
            20.1.8.4. Sales Footprint
            20.1.8.5. Strategy Overview
                20.1.8.5.1. Marketing Strategy
        20.1.9. QIAGEN N.V.
            20.1.9.1. Overview
            20.1.9.2. Product Portfolio
            20.1.9.3. Profitability by Market Segments
            20.1.9.4. Sales Footprint
            20.1.9.5. Strategy Overview
                20.1.9.5.1. Marketing Strategy
        20.1.10. Charles River Laboratories
            20.1.10.1. Overview
            20.1.10.2. Product Portfolio
            20.1.10.3. Profitability by Market Segments
            20.1.10.4. Sales Footprint
            20.1.10.5. Strategy Overview
                20.1.10.5.1. Marketing Strategy
21. Assumptions & Acronyms Used
22. Research Methodology
Recommendations

Healthcare

Lateral Flow Assays Market

August 2023

REP-GB-14271

325 pages

Healthcare

Angiogenesis Assays Market

July 2023

REP-GB-10030

250 pages

Healthcare

Immunology-oncology ELISA Kits Market

December 2024

REP-GB-12084

Upcoming

Healthcare

Cytotoxicity Assays Market

December 2024

REP-GB-10024

Upcoming

Explore Healthcare Insights

View Reports
Future Market Insights

Immuno Oncology Assay Market

Schedule a Call